812-antibody microarray (Kinexus Bioinformatics Corporation)
90
Structured Review
Kinexus Bioinformatics Corporation
812-antibody microarray
812 Antibody Microarray, supplied by Kinexus Bioinformatics Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/812-antibody+microarray/628+antibody+microarray/us09556101-303-1-0
Average 90 stars, based on 1 article reviews
812 Antibody Microarray, supplied by Kinexus Bioinformatics Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/812-antibody+microarray/628+antibody+microarray/us09556101-303-1-0
Average 90 stars, based on 1 article reviews
812-antibody microarray - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Microarray:Article Title: Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine Article Snippet: In brief, 1.5X106 UACC 903 cells were plated in 100 mm dishes and 48 hours later, treated with 3 μmol/L leelamine for 3-24 hours, Article Title: Compositions and methods relating to proliferative diseases Article Snippet: Article Title: Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine Article Snippet: Indirect Immunoperoxidase Assay:Article Title: Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine Article Snippet: In brief, 1.5X106 UACC 903 cells were plated in 100 mm dishes and 48 hours later, treated with 3 μmol/L leelamine for 3-24 hours, Article Title: Compositions and methods relating to proliferative diseases Article Snippet: Article Title: Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine Article Snippet: Software:Article Title: Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine Article Snippet: In brief, 1.5X106 UACC 903 cells were plated in 100 mm dishes and 48 hours later, treated with 3 μmol/L leelamine for 3-24 hours, Article Title: Compositions and methods relating to proliferative diseases Article Snippet: Article Title: Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine Article Snippet: |